gene-therapy is the sole category represented across all 1 tracked stories. Broadcom is most often covered alongside KRESLADI, which appears in 1 of these 1 story. Source depth averages 2 original sources per story, versus 2.6 across the same-window beat baseline.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Broadcom
gene-therapy is the sole category represented across all 1 tracked stories. Broadcom is most often covered alongside KRESLADI, which appears in 1 of these 1 story. Source depth averages 2 original sources per story, versus 2.6 across the same-window beat baseline. The 5 average consequence score is below the beat benchmark of 6 in the same window. Broadcom appears in 1 tracked Biotech story from March 19, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Broadcom. Shared-story counts are live from our verified record — not editorial picks.
Rocket Pharmaceuticals (RCKT) shares declined 4.4% on March 19, 2026, as investors weighed a recent shift in the company's financial agreements against ongoing regulatory timelines for its lead gene therapy programs. The drop outpaced broader market movements, reflecting specific volatility in the rare disease gene therapy sector.